FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $17.79M
• Dividend Yield: N/A
• Average Volume (3M): 978.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: 18.47%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 67,594,720
• 10 Day Avg. Volume: 1,423,641
• 30 Day Avg. Volume: 978,931
• PEG Ratio: -0.02
• Price to Book (P/B): 1.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.60
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: $2.75
• Price Target Upside: 957.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.26 ▼(-1.54% Downside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), supported only modestly by improved 2025 balance sheet leverage. Technicals remain bearish with the stock trading below all major moving averages and negative MACD. Corporate events further pressure the outlook due to Nasdaq delisting risk and reverse-split/dilution considerations, while valuation is difficult to justify given ongoing losses and no dividend support.

Positive Factors

Intellectual Property

Issuance of a Canadian patent for cachexia treatment strengthens the company’s IP portfolio and creates a durable asset that supports clinical development, potential licensing, and future partner interest. Patent protection can extend exclusivity and enhance long-term strategic optionality.

Improved Balance Sheet Leverage

Material reduction in debt and return to positive equity meaningfully lowers leverage versus 2024, improving solvency and negotiating position with lenders and partners. This structural improvement reduces short-term default risk and extends operational runway if burn is managed.

Capital-Structure Flexibility

Stockholder approval for a reverse split and warrant issuances gives management explicit tools to address listing compliance and to honor financing arrangements. This structural flexibility improves the company’s capacity to execute recapitalizations or financing without further procedural delays.

Negative Factors

Pre-Revenue Profile

The company remains pre-revenue through 2025, implying a long commercialization timeline and dependence on successful clinical outcomes. Absent product sales, sustainable profitability relies entirely on trial success, partnerships or asset sales, raising long-term execution risk.

Negative Cash Flow & Rising Burn

Operating and free cash flow worsened materially in 2025, signaling growing funding needs. Persistent negative cash generation forces reliance on external financing, increasing dilution risk and constraining R&D prioritization, which can impede steady clinical progress and strategic planning.

Listing/Delisting Uncertainty

Ongoing Nasdaq noncompliance and a formal delisting review create structural liquidity and reputational risks. Continued uncertainty around listing status can limit access to capital markets, hamper institutional interest, and raise financing costs, affecting long-term operational flexibility.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its fibroblast-based therapies. The company may earn income through licensing agreements, partnerships with pharmaceutical companies, and the sale of its therapeutic products once they receive regulatory approval. Additionally, FibroBiologics might secure funding through research grants, equity investments, and collaborations with academic institutions or healthcare organizations. These partnerships and investments support the company's research and development efforts, facilitating the advancement of its innovative therapies to the market.

FibroBiologics, Inc. Financial Statement Overview

Summary

Pre-revenue profile with no revenue reported (2020–2025), widening losses (net income down to -$18.6M in 2025) and worsening operating/free cash flow (OCF -$16.4M; FCF -$16.7M in 2025) signal high funding dependence. A key offset is improved balance sheet leverage in 2025 (debt reduced to $2.4M and positive equity around $6.2M), but overall financial strength remains weak due to accelerating cash burn.

Income Statement

The company reports no revenue across 2020–2025, consistent with an early-stage biotechnology profile. Losses have widened materially, with net income moving from -$1.2M (2020) to -$18.6M (2025), and EBIT also deteriorating (to -$16.6M in 2025). While R&D-driven investment can be expected in this industry, the absence of revenue and accelerating losses keep profitability and operating leverage weak.

Balance Sheet

Balance sheet risk has improved versus 2024: total debt fell to $2.4M in 2025 from $10.6M in 2024, and debt-to-equity improved to ~0.39 from ~3.86. Equity is positive in 2023–2025 (2025 equity ~$6.2M), a meaningful improvement from negative equity in 2021–2022, and total assets are ~$9.6M in 2025. However, returns remain deeply negative given ongoing losses, and the company’s financial position is still sensitive to continued cash burn and funding needs.

Cash Flow

Cash generation remains weak with operating cash flow negative each year and worsening to -$16.4M in 2025 (from -$11.9M in 2024). Free cash flow is also negative and declined to -$16.7M in 2025, with a slight additional contraction versus 2024. While free cash flow roughly tracks net losses (free cash flow to net income ~1.02 in 2025), the overall trajectory indicates increasing cash burn, implying reliance on external financing to sustain operations.

Breakdown	Dec 2025	Mar 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-832.00K	0.00	0.00	0.00	0.00
EBITDA	-17.61M	-10.57M	-15.90M	-4.37M	-1.58M
Net Income	-18.65M	-11.16M	-16.48M	-5.12M	-1.58M
Balance Sheet
Total Assets	9.62M	16.45M	11.82M	4.82M	468.00K
Cash, Cash Equivalents and Short-Term Investments	4.89M	13.98M	9.16M	2.27M	407.00K
Total Debt	2.41M	10.55M	1.75M	7.52M	1.30M
Total Liabilities	3.46M	13.71M	10.57M	8.82M	1.76M
Stockholders Equity	6.16M	2.73M	1.25M	-4.00M	-1.29M
Cash Flow
Free Cash Flow	-16.66M	-12.09M	-6.90M	-4.07M	-1.41M
Operating Cash Flow	-16.39M	-11.90M	-6.40M	-4.07M	-1.41M
Investing Cash Flow	-262.00K	-184.00K	-495.00K	0.00	0.00
Financing Cash Flow	7.57M	16.91M	13.79M	5.92M	1.82M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Neutral. The current price of 0.26 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.29, and below the 200-day MA of 0.50, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.29 is Neutral, neither overbought nor oversold. The STOCH value of 53.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	48 Neutral	$11.83M	-2.02	-22.03%	―	-41.76%	87.36%
CRIS	45 Neutral	$14.83M	-0.29	―	―	13.56%	52.92%
FBLG	42 Neutral	$17.79M	-0.60	-1292.87%	―	―	18.47%
PCSA	41 Neutral	$4.40M	―	-270.74%	―	―	72.88%
SYBX	40 Underperform	$7.25M	-2.34	-27.54%	―	-100.00%	93.62%

FibroBiologics, Inc. Corporate Events

FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances

FibroBiologics, Inc. reported that at a special meeting of stockholders held on February 20, 2026, investors approved an amendment to its certificate of incorporation authorizing the board to implement a reverse stock split in a range of 1-for-5 to 1-for-30 at its discretion within one year. Stockholders also approved multiple issuances of common shares underlying outstanding warrants tied to prior securities purchase agreements from November and December 2025, as well as related bank engagement warrants.

These approvals give the board flexibility to manage FibroBiologics’ capital structure and share price, while clearing the way for the company to honor warrant exercises and secure previously arranged financing under Nasdaq’s shareholder approval rules. Investors additionally authorized potential adjournments of the special meeting to solicit more votes if needed, signaling broad support for the company’s financing and capital-management strategy.

The most recent analyst rating on (FBLG) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Faces Nasdaq Delisting Review After Noncompliance

On August 4, 2025, FibroBiologics, Inc. was notified by Nasdaq that its market value of listed securities had fallen below the required $35 million minimum for 30 consecutive trading days, triggering a 180-day grace period through February 2, 2026, to regain compliance. On February 3, 2026, Nasdaq staff issued a formal notice that the company’s continued non-compliance with the market value rule now constitutes an additional basis for delisting, alongside a previously disclosed bid price deficiency. The matter is currently before a Nasdaq Hearings Panel, which will review FibroBiologics’ plan to restore compliance, and the company’s stock will remain listed and trading at least until the panel issues a decision and any potential extension expires. As part of its efforts, FibroBiologics filed definitive proxy materials on December 29, 2025, seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, although there is no assurance the company will obtain an extension or successfully meet the listing standards, leaving investors facing ongoing uncertainty over the firm’s Nasdaq listing status.

The most recent analyst rating on (FBLG) stock is a Hold with a $0.27 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Faces Nasdaq Delisting, Plans Reverse Split

On July 1, 2025, FibroBiologics, Inc. was notified by Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive trading days, triggering a 180-day grace period, through December 29, 2025, to regain compliance. After the company failed to meet the requirement by that deadline, Nasdaq staff notified FibroBiologics on December 30, 2025, of its intention to delist the stock unless the company requested a hearing, which FibroBiologics plans to do, temporarily staying any suspension or delisting. The company is monitoring its share price and, as part of its efforts to regain compliance, filed definitive proxy materials on December 29, 2025 seeking shareholder approval for a reverse stock split at a ratio between 1-for-5 and 1-for-30, though there is no assurance it will secure an extension or that these measures will succeed, leaving its Nasdaq listing status uncertain for investors.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Enters Securities Purchase Agreement

On December 14, 2025, FibroBiologics, Inc. entered into a securities purchase agreement with institutional investors to issue and sell 5,227,275 shares of common stock at $0.33 per share in a registered direct offering, alongside issuing warrants for the same number of shares in a concurrent private placement. The gross proceeds from these offerings are expected to be approximately $1.7 million, with potential additional proceeds if warrants are exercised. The company plans to use the net proceeds for working capital and general corporate purposes, and the offerings are expected to close around December 16, 2025, subject to customary conditions.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.

FibroBiologics Announces Securities Purchase Agreement

On November 24, 2025, FibroBiologics, Inc. announced it entered into a securities purchase agreement with institutional investors for a registered direct offering of 4,477,614 shares of common stock at $0.335 per share, expected to raise approximately $1.5 million. Additionally, in a concurrent private placement, the company will issue warrants for the same number of shares, subject to stockholder approval. The proceeds will be used for working capital and general corporate purposes, with H.C. Wainwright & Co. acting as the exclusive placement agent. The offering is expected to close on or about November 25, 2025, pending customary closing conditions.

The most recent analyst rating on (FBLG) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on FibroBiologics, Inc. stock, see the FBLG Stock Forecast page.